FDA Approves Oral Aloxi to Prevent Chemo Nausea and Vomiting

Posted by Kate Murphy on August 25th, 2008
Tags: nausea, side effects

The Food and Drug Administration has approved an oral formulation of Aloxi® (palonosetron) to prevent nausea and vomiting from chemotherapy.  A single 5 milligram capsule reduces the risk of nausea during the first 24 hours after chemotherapy and for up to five days afterwards.  The medicine is taken about an hour before chemotherapy starts.

The most common side effects were headache, experienced by about four percent of patients and constipation in less than one percent.

Information from the FDA about the new oral Aloxi approval.

Intravenous Aloxi has been available since 2003 to manage both acute nausea and vomiting in the hours after chemotherapy and delayed nausea during following days.

The patient brochure for IV Aloxi provides additional help to manage chemotherapy-induced nausea including avoiding:

The brochure also suggests

The makers of Aloxi also provide a calendar that helps patients record vomiting, nausea, and how they felt in the days after chemotherapy.  The information can then be shared with the doctor or oncology nurse.

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions.

C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond where appropriate.

For the best response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe